Lilly issues "Dear Doctor" letter over risks of Zyprexa in adolescents
This article was originally published in Scrip
Lilly has issued a "Dear Doctor" letter regarding the use of its atypical antipsychotic Zyprexa (olanzapine) in adolescents to warn of the increased risk of weight gain and hyperlipidemia compared with its use in adults.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.